INC Research, Inc. Emphasizes Metrics to Help Determine Value of Outsourcing at Partnerships in Clinical Trials Europe 2010

November 16, 2010 |

2 min read

VIENNA, AUSTRIA--(Marketwire - November 16, 2010) -

Highlighted Links

INC Research, Inc., a therapeutically focused contract research organization (CRO) with a process for delivering reliable results, will be discussing the value of clinical trials outsourcing at the 9th Annual Partnerships in Clinical Trials, booth #103. Todd Esporas, executive director, Contracts & Functional Services, will be presenting a case study with Fred Naids, PhD, senior strategic sourcing director, Clinical Development Operations and Biometrics at Shire Pharmaceuticals, that focuses on how the two companies use agreed-upon key performance indicators (KPIs) to measure their strategic partnerships.

Esporas and Naids will review how each company has approached the trend towards strategic partnerships and will discuss the framework for measuring their partnership in the session, “Case Study: Robust KPIs to Measure If Your Strategic Partnership is Really Working” on 17 Nov at 17:10. They will present governance structures that support the measurement and evaluation of quality at both the project and strategic level. They will address at a fundamental level how sponsors and CROs can collect and use metrics moving forward and confidently answer the question, “Has outsourcing really achieved decreased costs and improved quality or is it just keeping down headcount?”

Esporas oversees INC Research’s business unit comprised of contract management, investigator site relationship, site payment administration and document control professionals globally through functional shared services hubs in Asia, Europe, North America and South America. His teams provide strategic functional alliance solutions through the Functional Service Provider (FSP) model for site contract/activation and maintenance services to a number of global customers.

Sponsors have been challenged to review their approach to key functional areas of clinical research that are not core to their clinical development business in an effort to dramatically improve efficiency. INC Research’s FSP model has proven to be an effective tool for this purpose and can have the effect of reduced costs (30-40% direct cost savings on top of larger indirect cost savings), faster cycle times and improved quality.

The end result of implementing a FSP approach is greater predictability and more consistent delivery of services across all protocols. INC Research currently operates global FSP hubs in Asia, Europe, North America, and South America. For more information on FSP services, click here.

About INC Research, Inc.
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women’s health trials. The company’s Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information please visit www.incresearch.com.